Skip Navigation


Carcinogenesis Advance Access originally published online on April 9, 2007
Carcinogenesis 2007 28(8):1646-1652; doi:10.1093/carcin/bgm083
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
28/8/1646    most recent
bgm083v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Guijarro, M. V.
Right arrow Articles by Carnero, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guijarro, M. V.
Right arrow Articles by Carnero, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

MAP17 overexpression is a common characteristic of carcinomas

Maria V. Guijarro, Juan F.M. Leal, Jesus Fominaya, Carmen Blanco-Aparicio, Soledad Alonso1, Matilde Lleonart2, Josep Castellvi2, Lidia Ruiz, Santiago Ramon y Cajal2 and Amancio Carnero*

Experimental Therapeutics Program
1 Molecular Pathology Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
2 Dpto. Anatomía Patológica, Hospital Vall d'Hebrón, Barcelona, Spain

* To whom correspondence should be addressed. Tel: +34 91 732 8021; Fax: +34 91 732 8051; Email: acarnero{at}cnio.es

We undertook a large-scale genetic screen to identify genes able to alter the cellular response to physiological signals and provide selective advantage once tumorigenesis has begun. We identified MAP17, a small 17 kDa non-glycosylated membrane protein previously identified, being overexpressed in carcinomas. We found that MAP17 is overexpressed in a great variety of human carcinomas. Immunohistochemical analysis of MAP17 during cancer progression shows, at least in prostate and ovarian carcinomas, that overexpression of the protein strongly correlates with tumoral progression (P < 0.0001). Many tumor cells also express MAP17 and its expression does not correlate with expression of SCL, a neighbor gene reported to be co-expressed in some hematopoietic cell lines. SCL neither is expressed in most MAP17-positive tumors, indicating the independent transcription of MAP17, at least in carcinomas. We cloned 5' genomic region to MAP17 and described the minimal promoter necessary to produce independent activation of MAP17. Moreover, we have found that MAP17 promoter is activated by oncogenes. Taken together, our data show an independent activation of MAP17 promoter that can be driven by oncogenes and that might explain the common overexpression of MAP17 in human carcinomas.

Abbreviations: RT–PCR, reverse transcription–polymerase chain reaction; TMA, tissue microarray

Received February 19, 2007; revised March 29, 2007; accepted March 29, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
M. E. Castro, I. Ferrer, A. Cascon, M. V. Guijarro, M. Lleonart, S. R. y Cajal, J. F.M. Leal, M. Robledo, and A. Carnero
PPP1CA contributes to the senescence program induced by oncogenic Ras
Carcinogenesis, March 1, 2008; 29(3): 491 - 499.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.